

Applicant : Andrew Baxte
Serial No. :
Filed : Herewith
Page : 4

At [REDACTED]'s Docket No.: 06275-233001

REMARKS

Claims 1 to 12 and 20-25 are pending in this application, claims 13-19 having been cancelled. Claims 3-6, 9, 10, 12-15, 20 and 21 are amended to delete multiple dependency. No new matter has been added.


Attached is a marked-up version of the changes being made by the current amendment.

Applicant asks that all pending claims be examined. Please apply any charges or credits to Deposit Account No. 06-1050.

Date:

June 22, 2001

Respectfully submitted,


Janis K. Fraser, Ph.D., J.D.
Reg. No. 34,819

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20274000.doc

Applicant : Andrew Baxter et al.
Serial No. :
Filed : Herewith
Page : 5

09/86884

Attorney's Docket No.: 06275-233001

531 Rec'd PCT 22 JUN 2001


Version with markings to show changes made

In the claims:

Cancel claims 13-19 without prejudice.

Claims 3-6, 9, 10, 12, 20 and 21 have been amended as follows:

3. (Amended) A compound of formula (I), according to Claim 1 [or Claim 2], in which the group A is substituted as shown below in formula (Ia), where B and D are selected from CR², S, O and NR²⁵, where R² is as defined in Claim 1 and R²⁵ is hydrogen or C₁-C₆ alkyl:




4. (Amended) A compound according to [any one of Claims 1 to 3] claim 1 in which the ring A is thiophene.

5. (Amended) A compound according to [any one of Claims 1 to 4] claim 1 in which R¹ represents optionally substituted phenyl.

6. (Amended) A compound according to [any one of Claims 1 to 5] claim 1 in which R² represents H or methyl.


9. (Amended) A process for the preparation of a compound of formula (I), according to [any one of Claims 1 to 8] claim 1, which comprises:

(a) reaction of a compound of formula (II):




wherein A, R¹ and R² are as defined in Claim 1 with an isocyanate (X = O) or an isothiocyanate (X = S); or

(b) reaction of compound of formula (III) with a compound of formula (IV)



wherein A, X, R¹ and R² are as defined in Claim 1 and LG represents a leaving group; or

(c) reaction of compound of formula (V) with a compound of formula (VI)



wherein A, X, R¹ and R² are as defined in Claim 1 and LG represents a leaving group;
and where necessary converting the resultant compound of formula (I), or another salt

thereof, into a pharmaceutically acceptable salt thereof; or converting the resultant compound of formula (I) into a further compound of formula (I); and where desired converting the resultant compound of formula (I) into an optical isomer thereof.

10. (Amended) A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in [any one of claims 1 to 8] claim 1, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

12. (Amended) A compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as claimed in [any one of claims 1 to 8] claim 1 for use in therapy.

20. (Amended) A method of treating an IKK2 mediated disease which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in [any one of claims 1 to 8] claim 1.

21. (Amended) A method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in [any one of claims 1 to 8] claim 1.